Futura Medical PLC Block Listing Six Monthly Return (0106H)
01 Dicembre 2020 - 8:00AM
UK Regulatory
TIDMFUM
RNS Number : 0106H
Futura Medical PLC
01 December 2020
Block Listing Six Monthly Return
1 December 2020
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a
pharmaceutical company developing a portfolio of innovative
products for sexual health and pain relief, makes the following
update on its block listings, pursuant to AIM Rule 29 and Schedule
Six of the AIM Rules for Companies. All figures relate to options
over Ordinary Shares of 0.2 pence each (Ordinary Shares).
Date: 1 June 2020
Name of applicant: Futura Medical Plc
Name of scheme: Unapproved Share Option Scheme
Unapproved Share Incentive Scheme
EMI Share Option Scheme
---------------------------------------
Period of return: From: 1 June 2020 To: 30 November 2020
----------------------- ------------- ---- ------------------
Balance of unallotted securities under scheme(s) from previous return: 9,306,779
---------------------------------------
Plus: The amount by which the block scheme(s) has been increased since the n/a
date of the last
return (if any increase has been applied for):
---------------------------------------
Less: Number of securities issued/allotted under scheme(s) during period: n/a
---------------------------------------
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 9,306,779
---------------------------------------
Number and class of securities originally admitted and the date of admission USOS Total: 3,882,912
814,424 25 May 2011
1,202,280 8 October 2013
1,466,208 25 May 2017
400,000 30 May 2018
USIS Total: 425,000
425,000 30 November 2018
EMI Total: 7,012,088
1,520,576 25 May 2011
1,467,720 8 October 2013
1,893,792 25 May 2017
790,000 30 May 2018
1,340,000 30 November 2018
---------------------------------------
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
Nominated Adviser and Sole Broker:
Liberum
Bidhi Bhoma/ Euan Brown
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Supriya Mathur
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144
Notes to editors:
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys (R) technology. Each DermaSys(R)
formulation is separately patented and specifically tailored for
the selected indication and application, as well as being optimised
for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and
consumer healthcare markets as appropriate. Current therapeutic
areas are sexual health, including erectile dysfunction, and pain
relief. Development and commercialisation strategies are designed
to maximise product differentiation and value creation whilst
minimising risk.
MED3000 is Futura's topical gel formulation that is a
breakthrough treatment for erectile dysfunction (ED) through a
unique evaporative mode of action. Futura has conducted a Phase 3
study using MED3000 in ED, referred to as "FM57". This was a 1,000
patient, dose-ranging, multi-centre, randomised, double blind,
placebo-controlled, home use, parallel group study delivering
highly statistically significant results compared to pre-treatment
baseline, consistently meeting all co-primary endpoints of IIEF,
SEP2 and SEP3 (internationally accepted clinical trial endpoints in
ED) with over 60% of patients experiencing a clinically meaningful
improvement in their ED. MED3000 also begins to work immediately in
some patients, with 60% of patients seeing onset of their erection
within 10 minutes of application.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BLRBMBPTMTTJBAM
(END) Dow Jones Newswires
December 01, 2020 02:00 ET (07:00 GMT)
Grafico Azioni Futura Medical (LSE:FUM)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Futura Medical (LSE:FUM)
Storico
Da Apr 2023 a Apr 2024
